Identification of diet-derived constituents as potent inhibitors of intestinal glucuronidation

Drug Metabolism and Disposition

Volumn 42, Issue 10, 2014, Pages 1675-1683

  Gufford, Brandon T ^a   Chen, Gang ^a   Lazarus, Philip ^a   Graf, Tyler N ^b   Oberlies, Nicholas H ^b   Paine, Mary F ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b UNIVERSITY OF NORTH CAROLINA AT GREENSBORO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APIGENIN; AURANTIIN; DICLOFENAC; EPIGALLOCATECHIN GALLATE; FLAVONOLIGNAN; GLUCURONOSYLTRANSFERASE; HYMECROMONE; ISOSILYBIN A; ISOSILYBIN B; ISOSILYCHRISTIN; KAEMPFEROL; NARINGENIN; NICARDIPINE; PLANT MEDICINAL PRODUCT; QUERCETIN; SILIBININ; SILICRISTIN; SILIDIANIN; SILYBIN A; SILYBIN B; SILYMARIN; UNCLASSIFIED DRUG; ENZYME INHIBITOR; XENOBIOTIC AGENT;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DETERMINATION; DRUG GLUCURONIDATION; DRUG INHIBITION; DRUG POTENCY; EMBRYO; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IC50; INTESTINE; INTESTINE MICROSOME; KIDNEY CELL; LIVER MICROSOME; MALE; MICROSOME; QUANTITATIVE ANALYSIS; SILYBUM MARIANUM; ADVERSE EFFECTS; ANTAGONISTS AND INHIBITORS; BEVERAGE; CELL LINE; DIET; DRUG EFFECTS; DRUG INTERACTION; GRAPEFRUIT; METABOLISM;

BEVERAGES; CELL LINE; CITRUS PARADISI; DIET; DRUG INTERACTIONS; ENZYME INHIBITORS; GLUCURONOSYLTRANSFERASE; HUMANS; HYMECROMONE; INHIBITORY CONCENTRATION 50; INTESTINES; MICROSOMES; SILYMARIN; XENOBIOTICS;

EID: 84907911185     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.114.059451     Document Type: Article

References (53)

1. Bailey DG, Dresser G, and Arnold JM (2013) Grapefruit-medication interactions: forbidden fruit or avoidable consequences? CMAJ 185:309-316.
2. Biasutto L and Zoratti M (2014) Prodrugs of quercetin and resveratrol: a strategy under development. Curr Drug Metab 15:77-95.
3. Brantley SJ, Argikar AA, Lin YS, Nagar S, and Paine MF (2014a) Herb-drug interactions: challenges and opportunities for improved predictions. Drug Metab Dispos 42:301-317.
4. Brantley SJ, Graf TN, Oberlies NH, and Paine MF (2013) A systematic approach to evaluate herb-drug interaction mechanisms: investigation of milk thistle extracts and eight isolated constituents as CYP3A inhibitors. Drug Metab Dispos 41:1662-1670.
5. Brantley SJ, Gufford BT, Dua R, Fediuk DJ, Graf TN, Scarlett YV, Frederick KS, Fisher MB, Oberlies NH, and Paine MF (2014b) Physiologically based pharmacokinetic modeling framework for quantitative prediction of an herb-drug interaction. CPT Pharmacometrics Syst Pharmacol 3:e107.
6. Brantley SJ, Oberlies NH, Kroll DJ, and Paine MF (2010) Two flavonolignans from milk thistle (Silybum marianum) inhibit CYP2C9-mediated warfarin metabolism at clinically achievable concentrations. J Pharmacol Exp Ther 332:1081-1087.
7. Chengcheng G, Rui X, Tianheng M, Wei Y, and Liqun P (2013) Probe substrate and enzyme source-dependent inhibition of UDP-glucuronosyltransferase (UGT) 1A9 by wogonin. Afr Health Sci 13:551-555.
8. Court MH (2005) Isoform-selective probe substrates for in vitro studies of human UDP-glucuronosyltransferases. Methods Enzymol 400:104-116.
9. Court MH, Zhang X, Ding X, Yee KK, Hesse LM, and Finel M (2012) Quantitative distribution of mRNAs encoding the 19 human UDP-glucuronosyltransferase enzymes in 26 adult and 3 fetal tissues. Xenobiotica 42:266-277.
10. Davis-Searles PR, Nakanishi Y, Kim NC, Graf TN, Oberlies NH, Wani MC, Wall ME, Agarwal R, and Kroll DJ (2005) Milk thistle and prostate cancer: differential effects of pure flavonolignans from Silybum marianum on antiproliferative end points in human prostate carcinoma cells. Cancer Res 65:4448-4457.
11. DeLean A, Munson PJ, and Rodbard D (1978) Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves. Am J Physiol 235:E97-E102.
12. Dong RH, Fang ZZ, Zhu LL, Liang SC, Ge GB, Yang L, and Liu ZY (2012) Investigation of UDP-glucuronosyltransferases (UGTs) inhibitory properties of carvacrol. Phytother Res 26: 86-90.
13. Erlund I, Meririnne E, Alfthan G, and Aro A (2001) Plasma kinetics and urinary excretion of the flavanones naringenin and hesperetin in humans after ingestion of orange juice and grapefruit juice. J Nutr 131:235-241.
14. Fallon JK, Neubert H, Goosen TC, and Smith PC (2013) Targeted precise quantification of 12 human recombinant uridine-diphosphate glucuronosyl transferase 1A and 2B isoforms using nano-ultra-high-performance liquid chromatography/tandem mass spectrometry with selected reaction monitoring. Drug Metab Dispos 41:2076-2080.
15. Fang ZZ, Cao YF, Hu CM, Hong M, Sun XY, Ge GB, Liu Y, Zhang YY, Yang L, and Sun HZ (2013) Structure-inhibition relationship of ginsenosides towards UDP-glucuronosyltransferases (UGTs). Toxicol Appl Pharmacol 267:149-154.
16. Fujiwara R, Nakajima M, Yamanaka H, Katoh M, and Yokoi T (2008) Product inhibition of UDP-glucuronosyltransferase (UGT) enzymes by UDP obfuscates the inhibitory effects of UGT substrates. Drug Metab Dispos 36:361-367.
17. Ghosal A, Hapangama N, Yuan Y, Achanfuo-Yeboah J, Iannucci R, Chowdhury S, Alton K, Patrick JE, and Zbaida S (2004) Identification of human UDP-glucuronosyltransferase enzyme (s) responsible for the glucuronidation of ezetimibe (Zetia). Drug Metab Dispos 32:314-320.
18. Graf TN, Wani MC, Agarwal R, Kroll DJ, and Oberlies NH (2007) Gram-scale purification of flavonolignan diastereoisomers from Silybum marianum (Milk Thistle) extract in support of preclinical in vivo studies for prostate cancer chemoprevention. Planta Med 73:1495-1501.
19. Gurley BJ, Fifer EK, and Gardner Z (2012) Pharmacokinetic herb-drug interactions (part 2): drug interactions involving popular botanical dietary supplements and their clinical relevance. Planta Med 78:1490-1514.
20. Gwilt PR, Lear CL, Tempero MA, Birt DD, Grandjean AC, Ruddon RW, and Nagel DL (1994) The effect of garlic extract on human metabolism of acetaminophen. Cancer Epidemiol Biomarkers Prev 3:155-160.
21. Hoh C, Boocock D, Marczylo T, Singh R, Berry DP, Dennison AR, Hemingway D, Miller A, West K, and Euden S, et al. (2006) Pilot study of oral silibinin, a putative chemopreventive agent, in colorectal cancer patients: silibinin levels in plasma, colorectum, and liver and their pharmacodynamic consequences. Clin Cancer Res 12:2944-2950.
22. Houston JB and Kenworthy KE (2000) In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model. Drug Metab Dispos 28:246-254.
23. Jančová P, Siller M, Anzenbacherová E, Křen V, Anzenbacher P, and Simánek V (2011) Evidence for differences in regioselective and stereoselective glucuronidation of silybin diastereomers from milk thistle (Silybum marianum) by human UDP-glucuronosyltransferases. Xenobiotica 41:743-751.
24. Kemp DC, Fan PW, and Stevens JC (2002) Characterization of raloxifene glucuronidation in vitro: contribution of intestinal metabolism to presystemic clearance. Drug Metab Dispos 30:694-700.
25. Kiang TK, Ensom MH, and Chang TK (2005) UDP-glucuronosyltransferases and clinical drugdrug interactions. Pharmacol Ther 106:97-132.
26. Kidd PM (2009) Bioavailability and activity of phytosome complexes from botanical polyphenols: the silymarin, curcumin, green tea, and grape seed extracts. Altern Med Rev 14: 226-246.
27. Kim E, Sy-Cordero A, Graf TN, Brantley SJ, Paine MF, and Oberlies NH (2011) Isolation and identification of intestinal CYP3A inhibitors from cranberry (Vaccinium macrocarpon) using human intestinal microsomes. Planta Med 77:265-270.
28. Kroll DJ, Shaw HS, and Oberlies NH (2007) Milk thistle nomenclature: why it matters in cancer research and pharmacokinetic studies. Integr Cancer Ther 6:110-119.
29. Lapham K, Bauman JN, Walsky RL, Niosi M, Orozco CC, Bourcier K, Giddens G, Obach RS, and Hyland R (2012) Digoxin and tranilast as novel isoform selective inhibitors of human UDP glucuronosyltransferase 1A9. Drug Metab Rev 44(Suppl):74-75.
30. Li L, Hu H, Xu S, Zhou Q, and Zeng S (2012) Roles of UDP-glucuronosyltransferases in phytochemical metabolism of herbal medicines and the associated herb-drug interactions. Curr Drug Metab 13:615-623.
31. Manach C, Williamson G, Morand C, Scalbert A, and Rémésy C (2005) Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. Am J Clin Nutr 81 (1 Suppl):230S-242S.
32. Mohamed MF and Frye RF (2010) Inhibition of intestinal and hepatic glucuronidation of mycophenolic acid by Ginkgo biloba extract and flavonoids. Drug Metab Dispos 38:270-275.
33. Mohamed ME and Frye RF (2011a) Effects of herbal supplements on drug glucuronidation. Review of clinical, animal, and in vitro studies. Planta Med 77:311-321.
34. Mohamed ME and Frye RF (2011b) Inhibitory effects of commonly used herbal extracts on UDPglucuronosyltransferase 1A4, 1A6, and 1A9 enzyme activities. Drug Metab Dispos 39: 1522-1528.
35. Mohamed MF, Tseng T, and Frye RF (2010) Inhibitory effects of commonly used herbal extracts on UGT1A1 enzyme activity. Xenobiotica 40:663-669.
36. Nair HB, Sung B, Yadav VR, Kannappan R, Chaturvedi MM, and Aggarwal BB (2010) Delivery of antiinflammatory nutraceuticals by nanoparticles for the prevention and treatment of cancer. Biochem Pharmacol 80:1833-1843.
37. Napolitano JG, Lankin DC, Graf TN, Friesen JB, Chen SN, McAlpine JB, Oberlies NH, and Pauli GF (2013) HiFSA fingerprinting applied to isomers with near-identical NMR spectra: the silybin/isosilybin case. J Org Chem 78:2827-2839.
38. Paine MF and Oberlies NH (2007) Clinical relevance of the small intestine as an organ of drug elimination: drug-fruit juice interactions. Expert Opin Drug Metab Toxicol 3:67-80.
39. Picard N, Ratanasavanh D, Prémaud A, Le Meur Y, and Marquet P (2005) Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug Metab Dispos 33:139-146.
40. Pietsch M, Christian L, Inhester T, Petzold S, and Gütschow M (2009) Kinetics of inhibition of acetylcholinesterase in the presence of acetonitrile. FEBS J 276:2292-2307.
41. Ritter JK (2007) Intestinal UGTs as potential modifiers of pharmacokinetics and biological responses to drugs and xenobiotics. Expert Opin Drug Metab Toxicol 3:93-107.
42. Sjögren E, Lennernäs H, Andersson TB, Gråsjö J, and Bredberg U (2009) The multiple depletion curves method provides accurate estimates of intrinsic clearance (CLint), maximum velocity of the metabolic reaction (Vmax), and Michaelis constant (Km): accuracy and robustness evaluated through experimental data and Monte Carlo simulations. Drug Metab Dispos 37:47-58.
43. Sun D, Jones NR, Manni A, and Lazarus P (2013) Characterization of raloxifene glucuronidation: potential role of UGT1A8 genotype on raloxifene metabolism in vivo. Cancer Prev Res (Phila) 6:719-730.
44. Tripathi SP, Bhadauriya A, Patil A, and Sangamwar AT (2013) Substrate selectivity of human intestinal UDP-glucuronosyltransferases (UGTs): in silico and in vitro insights. Drug Metab Rev 45:231-252.
45. Tukey RH and Strassburg CP (2000) Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu Rev Pharmacol Toxicol 40:581-616.
46. Uchaipichat V, Mackenzie PI, Guo XH, Gardner-Stephen D, Galetin A, Houston JB, and Miners JO (2004) Human UDP-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid. Drug Metab Dispos 32:413-423.
47. Ude C, Schubert-Zsilavecz M, and Wurglics M (2013) Ginkgo biloba extracts: a review of the pharmacokinetics of the active ingredients. Clin Pharmacokinet 52:727-749.
48. van Erp NP, Baker SD, Zhao M, Rudek MA, Guchelaar HJ, Nortier JW, Sparreboom A, and Gelderblom H (2005) Effect of milk thistle (Silybum marianum) on the pharmacokinetics of irinotecan. Clin Cancer Res 11:7800-7806.
49. Vandermolen KM, Cech NB, Paine MF, and Oberlies NH (2013) Rapid quantitation of furanocoumarins and flavonoids in grapefruit juice using ultra-performance liquid chromatography. Phytochem Anal 24:654-660.
50. Williams JA, Hyland R, Jones BC, Smith DA, Hurst S, Goosen TC, Peterkin V, Koup JR, and Ball SE (2004) Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos 32:1201-1208.
51. Won CS, Oberlies NH, and Paine MF (2012) Mechanisms underlying food-drug interactions: inhibition of intestinal metabolism and transport. Pharmacol Ther 136:186-201.
52. Wu B, Kulkarni K, Basu S, Zhang S, and Hu M (2011) First-pass metabolism via UDPglucuronosyltransferase: a barrier to oral bioavailability of phenolics. J Pharm Sci 100: 3655-3681.
53. Zhu HJ, Brinda BJ, Chavin KD, Bernstein HJ, Patrick KS, and Markowitz JS (2013) An assessment of pharmacokinetics and antioxidant activity of free silymarin flavonolignans in healthy volunteers: a dose escalation study. Drug Metab Dispos 41:1679-1685.